Glibornuride
Names | |
---|---|
IUPAC name
N-{[(1R,2R,3S,4S)-2-Hydroxybornan-3-yl]carbamoyl}-4-methylbenzene-1-sulfonamide
| |
Systematic IUPAC name
N-{[(1S,2S,3R,4R)-3-Hydroxy-4,7,7-trimethylbicyclo[2.2.1]heptan-2-yl]carbamoyl}-4-methylbenzene-1-sulfonamide | |
Identifiers | |
3D model (
JSmol ) |
|
ChemSpider | |
DrugBank | |
ECHA InfoCard
|
100.043.735 |
EC Number |
|
KEGG | |
MeSH | C073323 |
PubChem CID
|
|
UNII | |
| |
| |
Properties | |
C18H26N2O4S | |
Molar mass | 366.48 g/mol |
Pharmacology | |
A10BB04 (WHO) | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Glibornuride (
anti-diabetic drug from the group of sulfonylureas.[1] It is manufactured by MEDA Pharma and sold in Switzerland under the brand name Glutril.[2]
Synthesis
Gliburnide is an endo-endo derivative made from camphor-3-carboxamide by borohydride reduction (exo approach), followed by Hofmann rearrangement to carbamate, followed by displacement with sodium tosylamide.
References
- PMID 5004178.
- ^ "Glutril — Drugs.com". Drugs.com. Retrieved 12 July 2016.
- .